M. Miravitlles (Barcelona, Spain), M. Vendrell Relat (Girona, Spain)
A simple tool to predict hospital admissions in bronchiectasis
W. Salih, L. Popellwell, R. Stretton, J. Chalmers, T. Fardon (Dundee, United Kingdom)
|   |
Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis
R. Wilson, P. Reimnitz, E. Operschall, J. Alder (London, United Kingdom; Wuppertal, Berlin, Germany; Montville, United States Of America)
| |
Microbial aetiology and outcomes of CAP in bronchiectatic patients
E. Polverino, R. Menendez, C. Cilloniz, R. Amaro, A. Gabarrus, J. Puig de la Bellacasa, J. Sellares, B. Montull, J. Mensa, A. Torres (Barcelona, Valencia, Spain)
|  |
The impact of bronchiectasis on outcomes in a large cohort of patients hospitalised with exacerbations of COPD
R. Stretton, S. Schembri, P. Short, L. Poppelwell, A. Singnayagam, A. Akram, T. Fardon, J. Chalmers, P. Williamson (Dundee, London, Edinburgh, United Kingdom)
| |
Alterations to innate immunity in patients with bronchiectasis
M. Vendrell, P. Fernández, J. de Gracia, A. Alvarez, M. Buxó, G. Muñoz, S. Sendra, G. Sabater, J. M. Fernandez-Real (Girona, Barcelona, Spain)
| |
Bacterial etiology of exacerbations of non-cystic fibrosis bronchiectases in young patients
N. Rutenko, S. Baydurin, A. Baygenzhin (Astana, Kazakhstan)
| |
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
C. Haworth, D. Bilton, R. Kenyon (Cambridge, London, Chichester, United Kingdom)
| |
Predicting hospital admissions in non-CF bronchiectasis using COPD specific severity tools
L. Poppelwell, W. Salih, R. J. Stretton, K. Leighton, E. Furrie, S. Schembri, S. Marshall, T. C. Fardon, J. D. Chalmers (Dundee, United Kingdom)
| |